Xeris Biopharma Holdings, Inc. (FRA:2B30)
Germany flag Germany · Delayed Price · Currency is EUR
6.38
-0.04 (-0.70%)
At close: Jan 23, 2026

Xeris Biopharma Holdings Ratios and Metrics

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jan '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
1,028488294169321-
Market Cap Growth
118.96%66.23%73.53%-47.33%--
Enterprise Value
1,168683440211317-
Last Close Price
5.933.232.101.152.20-
PS Ratio
4.532.491.981.647.37-
PB Ratio
-1400.71-17.07-47.864.003.84-
EV/Sales Ratio
5.213.482.972.057.26-
Debt / Equity Ratio
-299.25-9.17-33.794.380.932.58
Asset Turnover
0.770.630.490.340.210.15
Inventory Turnover
0.730.850.901.061.011.77
Quick Ratio
1.251.121.172.081.524.99
Current Ratio
1.931.671.642.541.805.40
Return on Equity (ROE)
---324.20%-134.83%-190.28%-378.20%
Return on Assets (ROA)
2.88%-5.33%-8.25%-15.78%-28.45%-38.02%
Return on Capital Employed (ROCE)
6.30%-12.40%-19.40%-30.20%-46.80%-62.30%
Earnings Yield
-1.30%-10.85%-19.18%-52.34%-33.59%-
FCF Yield
0.83%-7.49%-15.18%-57.18%-26.44%-
Buyback Yield / Dilution
-8.48%-6.61%-1.51%-71.62%-85.32%-63.32%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.